EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2022 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New Jersey
This Employment Agreement (the “Agreement”), is entered into effective as of December 7, 2020 (the “Effective Date”), by and between Mereo BioPharma Group plc, a company incorporated in England and Wales (the “Company”) and Suba Krishnan (“Executive” and, together with the Company, the “Parties”).
THIS AMENDED AND RESTATED CONTRACT OF EMPLOYMENT dated August 2021 is madeMereo Biopharma Group PLC • March 31st, 2022 • Pharmaceutical preparations • England
This Contract sets out the terms and conditions of your employment with the Company at the date of this Contract and supersedes all previous arrangements or agreements whether oral or in writing between you and the Company in relation to the matters dealt with in it.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2022 • Mereo Biopharma Group PLC • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of September 1, 2019 (the “Effective Date”) by and between Mereo BioPharma Group Plc, a company incorporated in England and Wales (the “Company”), and John Richard (“Employee”).
LICENSE AGREEMENTLicense Agreement • March 31st, 2022 • Mereo Biopharma Group PLC • Pharmaceutical preparations • Delaware
This LICENSE AGREEMENT (the “Agreement”) is entered into on January 13, 2020 (the “Effective Date”) between ONCOMED PHARMACEUTICALS, INC., a Delaware corporation with a place of business at 800 Chesapeake Dr., Redwood City, CA, 94063 (“Licensor”), a wholly-owned subsidiary of MEREO BIOPHARMA GROUP PLC with a place of business at 1 Cavendish Place, London W1G 0QF, United Kingdom (“Mereo”), and ONCOLOGIE, INC., a Delaware corporation with a place of business at 400 Totten Pond Road, Suite 120, Waltham, MA 02451 (“Licensee”). Licensor and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
MEREO BIOPHARMA 5, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • March 31st, 2022 • Mereo Biopharma Group PLC • Pharmaceutical preparations
This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and among [name] (“Executive”), Mereo BioPharma 5, Inc. (the “Company”) and Mereo BioPharma Group plc (“Parent”), effective as of [date] (the “Effective Date”).
